[{"type": "title", "data": "CARD NSTEMI and Unstable Angina - Ongoing Management (Module)"}, {"type": "category", "data": "Admit/Transfer/Discharge"}, {"type": "note", "data": "Please ensure that one of the Cardiology Admission order sets is ordered prior to proceeding", "value": ""}, {"type": "note", "data": "Refer to Non-ST-Elevation Angina Management Algorithm", "value": ""}, {"type": "note", "data": "Calculate GRACE risk score on all NSTEMI patients: GRACE ACS Risk Model Calculator", "value": ""}, {"type": "note", "data": "Calculate Crusade bleeding risk score on all NSTEMI patients: Crusade Bleeding Risk Score Calculator", "value": ""}, {"type": "category", "data": "Medications"}, {"type": "note", "data": "Please ensure :  - loading  dose of antiplatelets have been administered  - selection of a daily antiplatelet (ASA, and either ticagrelor or clopidogrel) starting day after administering loading dose", "value": ""}, {"type": "order", "data": "ASA EC", "value": ""}, {"type": "sentence", "data": "81 mg, PO, qdaily, drug form: tab-EC"}, {"type": "note", "data": "For appropriately selected patients, dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin should be given. Use caution in patients at high risk of bleeding.  Routine pre-treatment with a P2Y12 receptor inhibitor in NSTEMI- ACS patients, in whom an early invasive management is planned and coronary anatomy is not known, is NOT RECOMMENDED given the lack of established benefit. However for patients with a planned delayed invasive management strategy (greater than 24 hours), P2Y12 receptor inhibitor may be considered based on thrombotic and bleed risk; AND likelihood of requiring urgent cardiac surgery in the next 5 days.", "value": ""}, {"type": "note", "data": "For patients requiring long term anticoagulation, clopidogrel is preferred  Avoid ticagrelor in patients with severe bradycardia (heart rate less than 50 bpm)", "value": ""}, {"type": "note", "data": "Hold ticagrelor or clopidogrel until after angiogram has been performed - PREFERRED", "value": ""}, {"type": "order", "data": "ticagrelor", "value": ""}, {"type": "sentence", "data": "90 mg, PO, BID, drug form: tab"}, {"type": "order", "data": "clopidogrel", "value": ""}, {"type": "sentence", "data": "75 mg, PO, qdaily, drug form: tab"}, {"type": "note", "data": "Glycoprotein IIb / IIIa Inhibitor (eptifibatide) therapy may be considered in very high risk patients awaiting PCI who have ongoing or recurrent ischemia despite dual antiplatelet therapy and an anticoagulant. Discuss with interventional or local cardiologist prior to ordering", "value": ""}, {"type": "note", "data": "Refer to CARD GP llb / llla inhibitor (eptifibatide) (Module)", "value": ""}, {"type": "note", "data": "No anticoagulation preferred if patient has a known bleeding disorder, or patient has a history of bleeding", "value": ""}, {"type": "note", "data": "Ensure initial dose of anticoagulants have been administered", "value": ""}, {"type": "order", "data": "Communication Order", "value": ""}, {"type": "sentence", "data": "No anticoagulation preferred, patient has a known bleeding disorder"}, {"type": "order", "data": "Communication Order", "value": ""}, {"type": "sentence", "data": "No anticoagulation preferred,  patient has a history of bleeding"}, {"type": "note", "data": "If anticoagulation required, select heparin OR enoxaparin OR fondaparinux", "value": ""}, {"type": "note", "data": "Heparin infusion is preferred for patients expected to go to the cath lab within 48 hours; or for patients with impaired renal function. Reassess 48 hours after initiation", "value": ""}, {"type": "note", "data": "Refer to Heparin Infusion Low PTT Target (Module) for heparin orders", "value": ""}, {"type": "note", "data": "Enoxaparin is INDICATED for patients requiring inter-facility transfer; medically managed patients; low to moderate risk of bleeding", "value": ""}, {"type": "note", "data": "Enoxaparin is CONTRAINDICATED if eGFR is less than 30 mL/min, known or suspected renal insufficiency. Use with caution if patient is over 75 years old", "value": ""}, {"type": "order", "data": "enoxaparin", "value": ""}, {"type": "sentence", "data": "1 mg/kg, subcutaneous, q12h, order duration: 8 day, drug form: inj"}, {"type": "note", "data": "Fondaparinux is INDICATED for medically managed patients not expected to go to the Cardiac Catheterization lab in the next 7 days; moderate to high risk of bleeding", "value": ""}, {"type": "note", "data": "Fondaparinux is CONTRAINDICATED if:  - EGFR is less than 30 mL/min  - Possibility of PCI in the next 7 days", "value": ""}, {"type": "order", "data": "fondaparinux", "value": ""}, {"type": "sentence", "data": "2.5 mg, subcutaneous, qPM, order duration: 8 day, drug form: syringe-inj"}, {"type": "note", "data": "Use atorvastatin 80 mg for ACS patients", "value": ""}, {"type": "order", "data": "atorvastatin", "value": "checked"}, {"type": "sentence", "data": "80 mg, PO, qdaily, drug form: tab"}, {"type": "sentence", "data": "40 mg, PO, qdaily, drug form: tab"}, {"type": "sentence", "data": "10 mg, PO, qdaily, drug form: tab"}, {"type": "order", "data": "rosuvastatin", "value": ""}, {"type": "sentence", "data": "40 mg, PO, qdaily, drug form: tab"}, {"type": "sentence", "data": "20 mg, PO, qdaily, drug form: tab"}, {"type": "sentence", "data": "10 mg, PO, qdaily, drug form: tab"}, {"type": "sentence", "data": "5 mg, PO, qdaily, drug form: tab"}, {"type": "note", "data": "caRVEDILOl target dose:  25 mg PO BID", "value": ""}, {"type": "order", "data": "caRVEDILOl", "value": ""}, {"type": "sentence", "data": "3.125 mg, PO, BID, drug form: tab"}, {"type": "sentence", "data": "6.25 mg, PO, BID, drug form: tab"}, {"type": "sentence", "data": "12.5 mg, PO, BID, drug form: tab"}, {"type": "sentence", "data": "25 mg, PO, BID, drug form: tab"}, {"type": "sentence", "data": "50 mg, PO, BID, drug form: tab"}, {"type": "note", "data": "bisOPROLOL target dose:  10 mg PO Daily", "value": ""}, {"type": "order", "data": "bisOPROLOL", "value": ""}, {"type": "sentence", "data": "2.5 mg, PO, qdaily, drug form: tab"}, {"type": "sentence", "data": "1.25 mg, PO, qdaily, drug form: tab"}, {"type": "sentence", "data": "5 mg, PO, qdaily, drug form: tab"}, {"type": "sentence", "data": "10 mg, PO, qdaily, drug form: tab"}, {"type": "note", "data": "metoprolol target dose: 100 mg PO BID", "value": ""}, {"type": "order", "data": "metoprolol", "value": ""}, {"type": "sentence", "data": "25 mg, PO, BID, drug form: tab"}, {"type": "sentence", "data": "12.5 mg, PO, BID, drug form: tab"}, {"type": "sentence", "data": "50 mg, PO, BID, drug form: tab"}, {"type": "sentence", "data": "100 mg, PO, BID, drug form: tab"}, {"type": "note", "data": "Re-assess therapy if serum creatinine increases by more than 30% or if serum potassium rises above 5.2 mmol/L", "value": ""}, {"type": "order", "data": "ramipril", "value": ""}, {"type": "sentence", "data": "2.5 mg, PO, BID, drug form: cap"}, {"type": "sentence", "data": "1.25 mg, PO, BID, drug form: cap"}, {"type": "sentence", "data": "5 mg, PO, BID, drug form: cap"}, {"type": "sentence", "data": "2.5 mg, PO, qdaily, drug form: cap"}, {"type": "sentence", "data": "5 mg, PO, qdaily, drug form: cap"}, {"type": "sentence", "data": "10 mg, PO, qdaily, drug form: cap"}, {"type": "order", "data": "perindopril", "value": ""}, {"type": "sentence", "data": "4 mg, PO, qdaily, drug form: tab"}, {"type": "sentence", "data": "2 mg, PO, qdaily, drug form: tab"}, {"type": "sentence", "data": "8 mg, PO, qdaily, drug form: tab"}, {"type": "note", "data": "Avoid combination of ACE Inhibitor with ARB", "value": ""}, {"type": "note", "data": "Angiotensin Receptor Blocker (ARB) - indicated for ACE- inhibitor intolerance", "value": ""}, {"type": "note", "data": "Re-assess therapy if serum creatinine increases by more than 30% or if serum potassium rises above 5.2 mmol/L", "value": ""}, {"type": "order", "data": "candesartan", "value": ""}, {"type": "sentence", "data": "8 mg, PO, qdaily, drug form: tab"}, {"type": "sentence", "data": "4 mg, PO, qdaily, drug form: tab"}, {"type": "sentence", "data": "16 mg, PO, qdaily, drug form: tab"}, {"type": "sentence", "data": "32 mg, PO, qdaily, drug form: tab"}, {"type": "order", "data": "valsartan", "value": ""}, {"type": "sentence", "data": "40 mg, PO, BID, drug form: tab"}, {"type": "sentence", "data": "80 mg, PO, BID, drug form: tab"}, {"type": "sentence", "data": "160 mg, PO, BID, drug form: tab"}, {"type": "order", "data": "losartan", "value": ""}, {"type": "sentence", "data": "25 mg, PO, qdaily, drug form: tab"}, {"type": "sentence", "data": "50 mg, PO, qdaily, drug form: tab"}, {"type": "sentence", "data": "75 mg, PO, qdaily, drug form: tab"}, {"type": "sentence", "data": "100 mg, PO, qdaily, drug form: tab"}, {"type": "note", "data": "Consider proton-pump inhibitor for those on dual antiplatelet therapy at high risk of bleeding, including history of GI bleed or Peptic ulcer disease, or multiple risk factors such as age greater than 65 years, concurrent oral NSAIDs, anticoagulation or corticosteroids", "value": ""}, {"type": "order", "data": "pantoprazole", "value": ""}, {"type": "sentence", "data": "40 mg, PO, qdaily, drug form: tab"}, {"type": "note", "data": "Avoid nitroglycerin if any of the following are present:   - SBP below 90 mmHg or if more than 30 mmHg drop from baseline  - Suspected right ventricular infarction  - Recent use of phosphodiesterase inhibitors: within 24 hours for sildenafil (VIAGRA) and vardenafil (LEVITRA), within 48 hours for tadalafil (CIALIS)", "value": ""}, {"type": "order", "data": "nitroglycerin 0.4 mg/spray spray", "value": ""}, {"type": "sentence", "data": "1 spray, sublingual, q5min, PRN pain-chest, order duration: 3 doses or times, drug form: spray"}, {"type": "order", "data": "nitroglycerin titratable infusion (0.2 mg/mL) in D5W standard", "value": ""}, {"type": "sentence", "data": "Titrate, IV, 10 mcg/min starting rate, 0 mcg/min minimum rate, 200 mcg/min maximum rate, titrate instructions: Titrate by 10 mcg/min, q5min PRN for symptoms of ischemia; maintain SPB above 90 mmHg"}, {"type": "sentence", "data": "50 mg"}, {"type": "order", "data": "aluminum-magnesium hydroxide 40 mg-40 mg/mL oral liq (ALMAGEL EQUIV)", "value": ""}, {"type": "sentence", "data": "30 mL, PO, q6h, PRN indigestion, drug form: oral liq"}, {"type": "order", "data": "lactulose 10 g/15 mL oral liq", "value": ""}, {"type": "sentence", "data": "10 g, PO, qHS, PRN constipation, drug form: oral liq"}, {"type": "sentence", "data": "20 g, PO, qHS, PRN constipation, drug form: oral liq"}, {"type": "order", "data": "docusate", "value": ""}, {"type": "sentence", "data": "200 mg, PO, qdaily, drug form: cap"}]
